MidaTech raises £32m IPO for nanomedicine development
This article was originally published in Scrip
Midatech has raised £32m in its initial public offering on the AIM market of the London Stock Exchange. The company develops 'nanomedicines' using its gold nanoparticle (GNP) technology. The nanoparticles are being developed to enhance the delivery of proven drugs and MidaTech has programs in diabetes and oncology.